Free Trial

Jack Allen Analyst Performance

Analyst at Robert W. Baird

Jack Allen is a stock analyst at Robert W. Baird in the medical sector, covering 3 publicly traded companies. Over the past year, Jack Allen has issued 3 stock ratings, including buy and hold recommendations. While full access to Jack Allen's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jack Allen's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
3 Last 0 Years
Buy Recommendations
66.67% 2 Buy Ratings
Companies Covered
3 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy66.7%2 ratings
Hold33.3%1 ratings
Sell0.0%0 ratings

Out of 3 total stock ratings issued by Jack Allen at Robert W. Baird, the majority (66.7%) have been Buy recommendations, followed by 33.3% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
3 companies

Jack Allen, an analyst at Robert W. Baird, currently covers 3 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
3 companies
100.0%

Jack Allen of Robert W. Baird specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
2 companies
66.7%
MED - GENERIC DRG
1 company
33.3%

Jack Allen's Ratings History at Robert W. Baird

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
10/2/2025Boost Price Target$4.72$12.00Outperform
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
5/14/2025Lower Price Target$1.13$9.00Outperform
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
5/14/2025Lower Price Target$1.00$4.00Neutral